Allianz Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.67M Buy
12,700
+1,300
+11% +$606K 0.01% 1105
2025
Q4
$5.17M Sell
11,400
-2,500
-18% -$1.08M 0.01% 1128
2025
Q3
$5.44M Sell
13,900
-2,900
-17% -$1.21M 0.01% 1080
2025
Q2
$7.48M Buy
16,800
+3,700
+28% +$1.71M 0.01% 922
2025
Q1
$6.35M Buy
13,100
+5,500
+72% +$2.56M 0.01% 986
2024
Q4
$3.06M Buy
7,600
+3,100
+69% +$1.44M ﹤0.01% 1256
2024
Q3
$2.09M Sell
4,500
-900
-17% -$432K ﹤0.01% 1396
2024
Q2
$2.53M Sell
5,400
-500
-8% -$217K ﹤0.01% 1230
2024
Q1
$2.47M Sell
5,900
-14,700
-71% -$6.21M ﹤0.01% 1115
2023
Q4
$8.38M Sell
20,600
-4,800
-19% -$1.77M 0.01% 738
2023
Q3
$8.83M Buy
25,400
+12,000
+90% +$4.2M 0.01% 765
2023
Q2
$4.72M Buy
13,400
+2,200
+20% +$741K 0.01% 890
2023
Q1
$3.53M Buy
11,200
+5,200
+87% +$1.56M 0.01% 1118
2022
Q4
$1.73M Buy
6,000
+3,000
+100% +$914K ﹤0.01% 1329
2022
Q3
$869K Buy
3,000
+2,500
+500% +$719K ﹤0.01% 1435
2022
Q2
$141K Sell
500
-1,800
-78% -$482K ﹤0.01% 2097
2022
Q1
$600K Sell
2,300
-3,700
-62% -$878K ﹤0.01% 2054
2021
Q4
$1.32M Sell
6,000
-1,200
-17% -$233K ﹤0.01% 1785
2021
Q3
$1.31M Buy
7,200
+3,600
+100% +$703K ﹤0.01% 1814
2021
Q2
$726K Sell
3,600
-600
-14% -$126K ﹤0.01% 1875
2021
Q1
$903K Buy
+4,200
New +$923K ﹤0.01% 1684
2020
Q3
Sell
-24,700
Closed -$7.17M 2418
2020
Q2
$7.17M Sell
24,700
-10,200
-29% -$2.77M 0.01% 1035
2020
Q1
$8.3M Sell
34,900
-18,800
-35% -$4.31M 0.01% 928
2019
Q4
$11.8M Buy
53,700
+9,400
+21% +$1.9M 0.01% 1045
2019
Q3
$7.5M Sell
44,300
-4,900
-10% -$867K 0.01% 1254
2019
Q2
$9.02M Buy
49,200
+2,000
+4% +$350K 0.01% 1235
2019
Q1
$8.68M Sell
47,200
-40,900
-46% -$7.55M 0.01% 1207
2018
Q4
$14.6M Sell
88,100
-24,700
-22% -$4.28M 0.02% 903
2018
Q3
$21.7M Sell
112,800
-18,300
-14% -$3.26M 0.02% 844
2018
Q2
$22.3M Buy
131,100
+3,900
+3% +$605K 0.02% 822
2018
Q1
$20.7M Sell
127,200
-218,800
-63% -$35.7M 0.02% 863
2017
Q4
$51.9M Buy
346,000
+26,300
+8% +$3.89M 0.04% 520
2017
Q3
$48.6M Buy
319,700
+64,500
+25% +$9.71M 0.04% 523
2017
Q2
$32.9M Buy
255,200
+26,300
+11% +$3.17M 0.03% 716
2017
Q1
$25M Sell
228,900
-136,600
-37% -$12M 0.02% 878
2016
Q4
$26.9M Buy
365,500
+121,400
+50% +$9.88M 0.02% 847
2016
Q3
$21.3M Sell
244,100
-13,700
-5% -$1.29M 0.02% 940
2016
Q2
$22.2M Buy
257,800
+173,600
+206% +$15M 0.02% 841
2016
Q1
$6.69M Buy
84,200
+21,300
+34% +$1.93M 0.01% 1325
2015
Q4
$7.92M Buy
62,900
+24,800
+65% +$2.99M 0.01% 1159
2015
Q3
$3.97M Sell
38,100
-15,600
-29% -$2M ﹤0.01% 1363
2015
Q2
$6.63M Buy
53,700
+23,900
+80% +$3.01M 0.01% 1279
2015
Q1
$3.52M Buy
29,800
+300
+1% +$35.9K ﹤0.01% 1347
2014
Q4
$3.5M Buy
29,500
+21,200
+255% +$2.39M ﹤0.01% 1342
2014
Q3
$932K Buy
+8,300
New +$790K ﹤0.01% 1684

Other funds holding VRTX

Allianz Asset Management's VRTX Position: Q1 2026 in Review

Allianz Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 5.3% in Q1 2026, selling an estimated $903K and leaving 34,339 shares worth $15.3M. The position accounts for 0.02% of the portfolio, ranked #705.

Allianz Asset Management first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $340M in Q3 2018. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Allianz Asset Management held 34,339 shares of Vertex Pharmaceuticals worth $15.3M as of Q1 2026.
  • Allianz Asset Management sold 1,937 Vertex Pharmaceuticals shares in Q1 2026, an estimated $903K.
  • Vertex Pharmaceuticals made up 0.02% of Allianz Asset Management's portfolio in Q1 2026, its #705 holding.
  • Allianz Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Allianz Asset Management's Vertex Pharmaceuticals position peaked at $340M in Q3 2018.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.